Skip to content

Study · Randomized controlled trial · n = 20 · 2019

6 results

Effects of Glucagon-Like Peptide-1 Receptor Agonists on Hypothalamic-Pituitary-Adrenal Axis in Healthy Volunteers.

Winzeler B, da Conceição I, Refardt J, Sailer CO, Dutilh G, Christ-Crain M

The Journal of clinical endocrinology and metabolism1 Jan 2019Cited by 16 (Europe PMC)

PMID30272170 (opens in a new tab)DOI10.1210/jc.2018-01420 (opens in a new tab)PepBankPUB-30272170
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In healthy volunteers, urinary free cortisol was similar with dulaglutide and placebo.

    In plain wordsIn healthy volunteers, urinary free cortisol was similar with dulaglutide and placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeUrinary free cortisol
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    1.5 mg once weekly · subcutaneous · 3 weeksAs given in this study (human).

    Measurements

    Median urinary free cortisol
    240 nmol/L
    dulaglutide
    Median urinary free cortisol
    188 nmol/L
    placebo

    Source sentences

    Summary
    Urinary free cortisol levels were similar under dulaglutide [median (interquartile range) 240 nmol/L (164, 324)] vs placebo [188 nmol/L (133, 338), P = 0.131].
    3 context sentences
    Summary · context
    Double-blind, randomized, crossover study.
    Summary · context
    Twenty healthy volunteers.
    Summary · context
    Dulaglutide (Trulicity®) 1.5 mg and placebo (0.9% sodium chloride) were given subcutaneously once weekly for 3 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In healthy volunteers, serum cortisol circadian rhythm was comparable with dulaglutide and placebo.

    In plain wordsIn healthy volunteers, daily blood cortisol patterns were similar with dulaglutide and placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeSerum cortisol circadian rhythm
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    1.5 mg once weekly · subcutaneous · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    The circadian rhythm of serum and salivary cortisol were comparable in both groups as were cortisol levels after dexamethasone [dulaglutide 28 nmol/L (22, 47.5) vs placebo 26.5 nmol/L (15.8, 45.5), P = 0.4].
    3 context sentences
    Summary · context
    Double-blind, randomized, crossover study.
    Summary · context
    Twenty healthy volunteers.
    Summary · context
    Dulaglutide (Trulicity®) 1.5 mg and placebo (0.9% sodium chloride) were given subcutaneously once weekly for 3 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In healthy volunteers, salivary cortisol circadian rhythm was comparable with dulaglutide and placebo.

    In plain wordsIn healthy volunteers, daily saliva cortisol patterns were similar with dulaglutide and placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeSalivary cortisol circadian rhythm
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    1.5 mg once weekly · subcutaneous · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    The circadian rhythm of serum and salivary cortisol were comparable in both groups as were cortisol levels after dexamethasone [dulaglutide 28 nmol/L (22, 47.5) vs placebo 26.5 nmol/L (15.8, 45.5), P = 0.4].
    3 context sentences
    Summary · context
    Double-blind, randomized, crossover study.
    Summary · context
    Twenty healthy volunteers.
    Summary · context
    Dulaglutide (Trulicity®) 1.5 mg and placebo (0.9% sodium chloride) were given subcutaneously once weekly for 3 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In healthy volunteers, cortisol after dexamethasone was comparable with dulaglutide and placebo.

    In plain wordsIn healthy volunteers, cortisol after dexamethasone was similar with dulaglutide and placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeCortisol after dexamethasone
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    1.5 mg once weekly · subcutaneous · 3 weeksAs given in this study (human).

    Measurements

    Cortisol
    28 nmol/L
    dulaglutide after dexamethasone
    Cortisol
    26.5 nmol/L
    placebo after dexamethasone

    Source sentences

    Summary
    The circadian rhythm of serum and salivary cortisol were comparable in both groups as were cortisol levels after dexamethasone [dulaglutide 28 nmol/L (22, 47.5) vs placebo 26.5 nmol/L (15.8, 45.5), P = 0.4].
    3 context sentences
    Summary · context
    Double-blind, randomized, crossover study.
    Summary · context
    Twenty healthy volunteers.
    Summary · context
    Dulaglutide (Trulicity®) 1.5 mg and placebo (0.9% sodium chloride) were given subcutaneously once weekly for 3 weeks.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In healthy volunteers, serum cortisol before ACTH stimulation did not differ significantly between dulaglutide and placebo.

    In plain wordsIn healthy volunteers, blood cortisol before ACTH stimulation was similar with dulaglutide and placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeSerum cortisol before ACTH
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    1.5 mg once weekly · subcutaneous · 3 weeksAs given in this study (human).

    Measurements

    Serum cortisol
    522 nmol/L
    dulaglutide before ACTH stimulation
    Serum cortisol
    530 nmol/L
    placebo before ACTH stimulation

    Source sentences

    Summary
    Serum cortisol levels in dulaglutide and placebo treated participants were 522 nmol (388, 710) and 530 nmol/L (394, 747), before (P = 0.6), and 658 nmol/L (604, 810) and 636 nmol/L (512, 910) after ACTH stimulation (P = 0.87).
    3 context sentences
    Summary · context
    Double-blind, randomized, crossover study.
    Summary · context
    Twenty healthy volunteers.
    Summary · context
    Dulaglutide (Trulicity®) 1.5 mg and placebo (0.9% sodium chloride) were given subcutaneously once weekly for 3 weeks.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In healthy volunteers, serum cortisol after ACTH stimulation did not differ significantly between dulaglutide and placebo.

    In plain wordsIn healthy volunteers, blood cortisol after ACTH stimulation was similar with dulaglutide and placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeSerum cortisol after ACTH
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    1.5 mg once weekly · subcutaneous · 3 weeksAs given in this study (human).

    Measurements

    Serum cortisol
    658 nmol/L
    dulaglutide after ACTH stimulation
    Serum cortisol
    636 nmol/L
    placebo after ACTH stimulation

    Source sentences

    Summary
    Serum cortisol levels in dulaglutide and placebo treated participants were 522 nmol (388, 710) and 530 nmol/L (394, 747), before (P = 0.6), and 658 nmol/L (604, 810) and 636 nmol/L (512, 910) after ACTH stimulation (P = 0.87).
    3 context sentences
    Summary · context
    Double-blind, randomized, crossover study.
    Summary · context
    Twenty healthy volunteers.
    Summary · context
    Dulaglutide (Trulicity®) 1.5 mg and placebo (0.9% sodium chloride) were given subcutaneously once weekly for 3 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.